drugset
drugset / Trial / NCT02875834

A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia

NCT02875834 ↗

Phase 3 Completed 267 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the efficacy of two different doses (5 and 10 g) of ZS orally administered once daily (qd) vs placebo in maintaining normokalemia in initially hyperkalemic patients having achieved normokalemia following two days of initial ZS therapy (10g TID).

Timeline

Start
2017-03-03
Primary completion
2018-02-14
Completion
2018-02-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Sodium Zirconium Cyclosilicate Other / unclassified 5 g Oral
Subject Sodium Zirconium Cyclosilicate Other / unclassified 10 g Oral

Indications

No indication recorded.